Trial
NCT00142168
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Dana-Farber Cancer Institute
Collaborators
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Celgene Corporation; Genentech, Inc.
Condition
Waldenstrom's Macroglobulinemia
Intervention
CC-5103 (lenalidomide)
Why stopped
Toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-21